Patents by Inventor Ettore Appella

Ettore Appella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids encoding a novel neutrophil chemotactic factor
    Patent number: 6376659
    Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity of NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: April 23, 2002
    Assignee: The United States of America, as represented by the Department of Health and Human Services
    Inventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
  • Methods for generating phosphorylation site-specific immunological reagents
    Patent number: 6309863
    Abstract: The present invention provides methods for generating phosphorylation site-specific immunological reagents. More specifically, a phosphopeptide mimetic is incorporated into a polypeptide in place of a phosphorylated amino acid. The polypeptide is used as antigen by standard methods to generate either monoclonal or polyclonal antibodies which cross-react with the naturally phosphorylated polypeptide. The phosphopeptide mimetic preferably contains a non-hydrolyzable linkage from the appropriate carbon atom of the amino acid residue to a phosphate group. A preferred linkage is a CF2 group. Such a linkage is used to generate the phosphoserine mimetic F2Pab, which is incorporated into a polypeptide sequence derived from p53 to produce antibodies which recognize a specific phosphorylation state of p53. A CF2 group linkage is also used to produce the phosphothreonine mimetic F2Pmb, and to produce the phosphotyrosine mimetic, F2Pmp.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: October 30, 2001
    Assignee: Brookhaven Science Associates
    Inventors: Carl W. Anderson, Ettore Appella, Kazuyasu Sakaguchi
  • Urokinase-type plasminogen activator receptor
    Patent number: 6248712
    Abstract: Activation of plasminogen to plasmin is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator receptor are provided.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: June 19, 2001
    Assignee: Cancerforskningsfondet af 1989
    Inventors: Keld Danø, Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, W.D. Schleuning, Niels Behrendt, Ebbe Rønne, Peter Kristensen, Jari Pöllänen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk Møller, Vincent Ellis, Leif Røge Lund, Michael Ploug, Charles Pyke, Lászl{acute over (o )} Patthy
  • Human derived monocyte attracting purified peptide products useful in a method of treating infection and neoplasms in a human body
    Patent number: 6090795
    Abstract: Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.
    Type: Grant
    Filed: April 15, 1991
    Date of Patent: July 18, 2000
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Teizo Yoshimura, Elizabeth A. Robinson, Ettore Appella, Edward J. Leonard
  • Method of treating inflammation with antibodies to neutrophil chemotactic factor
    Patent number: 5925352
    Abstract: An isloated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.
    Type: Grant
    Filed: September 23, 1997
    Date of Patent: July 20, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
  • Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
    Patent number: 5891664
    Abstract: Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: April 6, 1999
    Assignee: Cancerforskningsfondet af 1989
    Inventors: Keld Dan.o slashed., Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, Wolf-Dieter Schleuning, Niels Behrendt, Ebbe R.o slashed.nne, Peter Kristensen, Jari Pollanen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk M.o slashed.ller, Vincent Ellis, Leif R.o slashed.ge Lund, Michael Ploug, Charles Pyke, Laszlo Patthy
  • Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body
    Patent number: 5714578
    Abstract: Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with such peptides and monocyte chemoattractant products are additionally provided, as well as pharmaceutical compositions for the same.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 3, 1998
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Teizo Yoshimura, Elizabeth A. Robinson, Ettore Appella, Edward J. Leonard
  • Antibodies specific for neutrophic chemotactic factor
    Patent number: 5698196
    Abstract: The present invention relates to an isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete coding sequence for NCF.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 16, 1997
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
  • Neutrophil chemotactic factor
    Patent number: 5652338
    Abstract: An isolated, synthetic preparation of a novel neutrophil-specific chemotactic factor (NCF), monoclonal antibodies having specific binding affinity for NCF and a clone containing the complete cDNA coding sequence for NCF are disclosed.
    Type: Grant
    Filed: March 16, 1988
    Date of Patent: July 29, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Kouji Matsushima, Teizo Yoshimura, Edward J. Leonard, Joost Oppenheim, Ettore Appella, Stephen D. Showalter
  • Process for preparing human derived monocyte attracting purified peptide products useful in a method of treating infection and neoplasms in a human body
    Patent number: 5532144
    Abstract: Pure peptide products, derived from either human glioma cell line U-105MG or human peripheral blood mononuclear leukocytes are provided; the products have a molecular mass of about 8,400 daltons, and the products exhibit optimal monocyte chemotactic activity at a concentration of 1 nM. Methods of treating infection and neoplasms in a human body with the peptide products are additionally provided, as well as pharmaceutical compositions for the peptide products.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: July 2, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Teizo Yoshimura, Elizabeth A. Robinson, Ettore Appella, Edward J. Leonard